Article (Scientific journals)
Minitransplants: allogeneic stem cell transplantation with reduced toxicity.
Beguin, Yves; Baron, Frédéric
2003In Acta Clinica Belgica, 58 (1), p. 37-45
Peer Reviewed verified by ORBi
 

Files


Full Text
187-Author.pdf
Author preprint (96.05 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Graft vs Leukemia Effect; Hematologic Neoplasms/therapy; Humans; Immunosuppression; Middle Aged; Peripheral Blood Stem Cell Transplantation/adverse effects/methods; Transplantation, Homologous
Abstract :
[en] Allogeneic hematopoietic stem cell transplantation (HSCT) is used for the treatment of selected hematological malignancies. Its curative potential is based on two very different mechanisms, involving the conditioning regimen and the graft-versus-host reactions, respectively. The high-dose chemo-radiotherapy conditioning regimen is aimed at destroying tumor cells, ablating the host immune system (to prevent rejection) and eliminating the host bone marrow (to "make space" for donor stem cells). However, the definitive eradication of tumor cells is also largely mediated by an immune-mediated destruction of malignant cells by donor lymphocytes termed graft-versus-leukemia (GVL) or graft-versus-tumor (GVT) effect. However, because of its toxicity, conventional allogeneic HSCT is restricted to younger (< 55 years) and fitter patients. These observations led several groups to set up new (less toxic) transplant protocols based on a two step approach: first the use of immunosuppressive (but nonmyeloablative) conditioning regimens providing sufficient immunosuppression to achieve engraftment of allogeneic hematopoietic stem cells and, in a second step, destruction of malignant cells by the GVL effect. These transplants are called nonmyeloablative HSCT or reduced-conditioning HSCT or minitransplants. Preliminary results show that minitransplants are feasible with a relatively low transplant-related mortality (TRM) even in patients up to 70 years. In addition, strong anti-tumor responses are observed in several hematological malignancies as well as in some patients with renal cell carcinoma. As the benefits of minitransplants over alternative forms of treatment remain to be demonstrated, this strategy should be restricted to patients included in clinical trials.
Disciplines :
Hematology
Author, co-author :
Beguin, Yves  ;  Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Baron, Frédéric  ;  Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Language :
English
Title :
Minitransplants: allogeneic stem cell transplantation with reduced toxicity.
Publication date :
2003
Journal title :
Acta Clinica Belgica
ISSN :
0001-5512
Publisher :
Acta Clinica Belgica, Bruxelles, Belgium
Volume :
58
Issue :
1
Pages :
37-45
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 23 March 2009

Statistics


Number of views
48 (3 by ULiège)
Number of downloads
274 (2 by ULiège)

Scopus citations®
 
2
Scopus citations®
without self-citations
2
OpenCitations
 
0

Bibliography


Similar publications



Contact ORBi